A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection
This randomized controlled trial evaluated the efficacy of acetyl-L-carnitine (ALC) in treating antiretroviral toxic neuropathy in HIV-1 patients through a multicenter, double-blind, placebo-controlled design. The study found that ALC significantly improved neuropathic symptoms compared to placebo, suggesting its potential as a therapeutic option to enhance quality of life and treatment